2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Protease Activated Probes for Real-Time Ratiometric Imaging of Solid Tumors

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Surgery is the preferred treatment option for most solid tumors. However, inaccurate detection of cancer borders leads to either incomplete removal of malignant cells or excess excision of healthy tissue. While fluorescent contrast agents and imaging systems improve tumor visualization, they can suffer from low signal-to-background and are prone to technical artifacts. Ratiometric imaging has the potential to eliminate many of these issues such as uneven probe distribution, tissue autofluorescence, and changes in positioning of the light source. Here, we describe a strategy to convert quenched fluorescent probes into ratiometric contrast agents. Conversion of the cathepsin-activated probe, 6QC-Cy5, into a two-fluorophore probe, 6QC-RATIO, significantly improved signal-to-background in vitro and in a mouse subcutaneous breast tumor model. Tumor detection sensitivity was further enhanced using a dual-substrate AND-gate ratiometric probe, Death-Cat-RATIO, that fluoresces only after orthogonal processing by multiple tumor-specific proteases. We also designed and built a modular camera system that was coupled to the FDA-approved da Vinci Xi robot, to enable real-time imaging of ratiometric signals at video frame rates compatible with surgical workflows. Our results demonstrate that ratiometric camera systems and imaging probes have the potential to be clinically implemented to improve surgical resection of many types of cancer.

          Abstract

          This work introduces probes and a camera system that enable real-time ratiometric imaging of solid tumors in an intraoperative setting to overcome limitations of previous one dye systems.

          Related collections

          Most cited references47

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer treatment and survivorship statistics, 2019

          The number of cancer survivors continues to increase in the United States because of the growth and aging of the population as well as advances in early detection and treatment. To assist the public health community in better serving these individuals, the American Cancer Society and the National Cancer Institute collaborate every 3 years to estimate cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries; vital statistics from the Centers for Disease Control and Prevention's National Center for Health Statistics; and population projections from the US Census Bureau. Current treatment patterns based on information in the National Cancer Data Base are presented for the most prevalent cancer types. Cancer-related and treatment-related short-term, long-term, and late health effects are also briefly described. More than 16.9 million Americans (8.1 million males and 8.8 million females) with a history of cancer were alive on January 1, 2019; this number is projected to reach more than 22.1 million by January 1, 2030 based on the growth and aging of the population alone. The 3 most prevalent cancers in 2019 are prostate (3,650,030), colon and rectum (776,120), and melanoma of the skin (684,470) among males, and breast (3,861,520), uterine corpus (807,860), and colon and rectum (768,650) among females. More than one-half (56%) of survivors were diagnosed within the past 10 years, and almost two-thirds (64%) are aged 65 years or older. People with a history of cancer have unique medical and psychosocial needs that require proactive assessment and management by follow-up care providers. Although there are growing numbers of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence-based resources are needed to optimize care.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Nitric oxide and peroxynitrite in health and disease.

            The discovery that mammalian cells have the ability to synthesize the free radical nitric oxide (NO) has stimulated an extraordinary impetus for scientific research in all the fields of biology and medicine. Since its early description as an endothelial-derived relaxing factor, NO has emerged as a fundamental signaling device regulating virtually every critical cellular function, as well as a potent mediator of cellular damage in a wide range of conditions. Recent evidence indicates that most of the cytotoxicity attributed to NO is rather due to peroxynitrite, produced from the diffusion-controlled reaction between NO and another free radical, the superoxide anion. Peroxynitrite interacts with lipids, DNA, and proteins via direct oxidative reactions or via indirect, radical-mediated mechanisms. These reactions trigger cellular responses ranging from subtle modulations of cell signaling to overwhelming oxidative injury, committing cells to necrosis or apoptosis. In vivo, peroxynitrite generation represents a crucial pathogenic mechanism in conditions such as stroke, myocardial infarction, chronic heart failure, diabetes, circulatory shock, chronic inflammatory diseases, cancer, and neurodegenerative disorders. Hence, novel pharmacological strategies aimed at removing peroxynitrite might represent powerful therapeutic tools in the future. Evidence supporting these novel roles of NO and peroxynitrite is presented in detail in this review.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Image-guided cancer surgery using near-infrared fluorescence.

              Paradigm shifts in surgery arise when surgeons are empowered to perform surgery faster, better and less expensively than current standards. Optical imaging that exploits invisible near-infrared (NIR) fluorescent light (700-900 nm) has the potential to improve cancer surgery outcomes, minimize the time patients are under anaesthesia and lower health-care costs largely by way of its improved contrast and depth of tissue penetration relative to visible light. Accordingly, the past few years have witnessed an explosion of proof-of-concept clinical trials in the field. In this Review, we introduce the concept of NIR fluorescence imaging for cancer surgery, examine the clinical trial literature to date and outline the key issues pertaining to imaging system and contrast agent optimization. Although NIR seems to be superior to many traditional imaging techniques, its incorporation into routine care of patients with cancer depends on rigorous clinical trials and validation studies.
                Bookmark

                Author and article information

                Journal
                ACS Cent Sci
                ACS Cent Sci
                oc
                acscii
                ACS Central Science
                American Chemical Society
                2374-7943
                2374-7951
                04 May 2023
                24 May 2023
                : 9
                : 5
                : 1059-1069
                Affiliations
                []Department of Chemistry, Stanford University , Stanford, California 94305, United States
                []Program in Cancer Biology, Stanford University School of Medicine , Stanford, California 94305 United States
                [§ ]Department of Pathology, Stanford University School of Medicine , Stanford, California 94305, United States
                []Intuitive Surgical Inc. , Sunnyvale, California 94086, United States
                [# ]Department of Chemical and Systems Biology, Stanford University School of Medicine , Stanford, California 94305, United States
                []Department of Microbiology and Immunology, Stanford University School of Medicine , Stanford, California 94305, United States
                Author notes
                Author information
                https://orcid.org/0000-0002-9902-6176
                https://orcid.org/0000-0003-3753-4412
                Article
                10.1021/acscentsci.3c00261
                10214504
                37252358
                fb8eae23-7524-4d99-bb26-adc1b3cbec8a
                © 2023 The Authors. Published by American Chemical Society

                Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 28 February 2023
                Funding
                Funded by: National Cancer Institute, doi 10.13039/100000054;
                Award ID: P30 CA124435
                Funded by: NSF, doi NA;
                Award ID: DGE-1656518
                Funded by: National Institute of Biomedical Imaging and Bioengineering, doi 10.13039/100000070;
                Award ID: R01 EB028628
                Funded by: National Institute of General Medical Sciences, doi 10.13039/100000057;
                Award ID: T32 GM141819
                Funded by: National Cancer Institute, doi 10.13039/100000054;
                Award ID: T32 CA11868
                Funded by: National Cancer Institute, doi 10.13039/100000054;
                Award ID: T32 CA009302
                Categories
                Research Article
                Custom metadata
                oc3c00261
                oc3c00261

                Comments

                Comment on this article